We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $581M
1-Year Est. Return 373.68%
This Fund
S&P 500
This Quarter Est. Return
+35.11%
1 Year Est. Return
+373.68%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$581M
AUM Growth
+$58.2M
Cap. Flow
-$54.7M
Cap. Flow %
-9.43%
Top 10 Hldgs %
40.99%
Holding
116
New
34
Increased
19
Reduced
30
Closed
32

Top Buys

Rank Stock Value
1
TNGX icon
Tango Therapeutics
TNGX
+$25.3M
2
ERAS icon
Erasca
ERAS
+$19M
3
TYRA icon
Tyra Biosciences
TYRA
+$14.5M
4
TRAX
First Tracks Biotherapeutics
TRAX
+$11.6M
5
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$10.9M

Top Sells

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$38.5M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$28.4M
3
RVMD icon
Revolution Medicines
RVMD
+$17.8M
4
MBX
MBX Biosciences
MBX
+$14.9M
5
IMVT icon
Immunovant
IMVT
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.23%
2 Miscellaneous 0.45%
3 Financials 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBIO
51
Crescent Biopharma
CBIO
$788M
$3.28M 0.57%
+182,382
New +$3.56M
ARWR icon
52
Arrowhead Research
ARWR
$12B
$3.2M 0.55%
+39,198
New +$2.9M
KOD icon
53
Kodiak Sciences
KOD
$2.24B
$2.96M 0.51%
+75,872
New +$2.95M
PHVS icon
54
Pharvaris
PHVS
$2.53B
$2.8M 0.48%
80,907
-5,730
-7% -$173K
MNPR icon
55
Monopar Therapeutics
MNPR
$783M
$2.79M 0.48%
+30,125
New +$1.86M
RAPP
56
Rapport Therapeutics
RAPP
$2.28B
$2.77M 0.48%
+66,582
New +$2.45M
NAMS icon
57
NewAmsterdam Pharma
NAMS
$3.01B
$2.63M 0.45%
77,589
-103,069
-57% -$3.4M
SION
58
Sionna Therapeutics
SION
$320M
$2.61M 0.45%
59,426
+22,886
+63% +$916K
ARQT icon
59
Arcutis Biotherapeutics
ARQT
$2.99B
$2.59M 0.45%
98,945
-314,847
-76% -$7.33M
CCCC icon
60
C4 Therapeutics
CCCC
$456M
$2.45M 0.42%
523,648
+70,412
+16% +$241K
SPRB
61
Spruce Biosciences
SPRB
$166M
$2.23M 0.39%
41,388
+35,028
+551% +$1.96M
CUE icon
62
Cue Biopharma
CUE
$198M
$2.11M 0.36%
+66,995
New +$1.51M
GPCR icon
63
Structure Therapeutics
GPCR
$3.34B
$2.05M 0.35%
38,178
-162,089
-81% -$7.17M
PTGX icon
64
Protagonist Therapeutics
PTGX
$9.45B
$2M 0.34%
16,303
-56,274
-78% -$5.88M
HLXC
65
Helix Acquisition Corp III
HLXC
$1.83M 0.31%
171,671
-133,357
-44% -$1.37M
BDSX icon
66
Biodesix
BDSX
$279M
$1.58M 0.27%
70,000
-4
-0% -$59
TENX icon
67
Tenax Therapeutics
TENX
$68.1M
$1.4M 0.24%
96,273
-92,427
-49% -$1.18M
SABS icon
68
SAB Biotherapeutics
SABS
$340M
$1.34M 0.23%
342,631
-32,369
-9% -$120K
CALC icon
69
CalciMedica
CALC
$15.3M
$1.2M 0.21%
+248,973
New +$883K
LBRX
70
LB Pharmaceuticals
LBRX
$1.55B
$1.03M 0.18%
31,785
-18,215
-36% -$535K
CLRB icon
71
Cellectar Biosciences
CLRB
$22.2M
$987K 0.17%
+354,938
New +$993K
PSNL icon
72
CALL
Personalis
PSNL
$1.79B
$811K 0.14%
+470,000
New +$3.83M
PRQR icon
73
ProQR Therapeutics
PRQR
$295M
$802K 0.14%
+431,054
New +$710K
BHVN icon
74
CALL
Biohaven
BHVN
$2.34B
$525K 0.09%
+500,000
New +$5.38M
XBI icon
75
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.6B
$400K 0.07%
+250,000
New +$33.8M
1 2
3
4 5

Similar funds

PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
Cambridge Advisors Omaha, Nebraska $582M AUM 19.14% 1-Year Est. Return

Stempoint Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Stempoint Capital held 116 positions worth $581M, up 11% from $522M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Stempoint Capital withdrew a net $54.7M in Q2 2026, closing 32 positions and reducing 30 holdings. Its most notable exit was Syndax Pharmaceuticals, an estimated $28.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Stempoint Capital opened a new position in First Tracks Biotherapeutics worth $12.5M.

  • Stempoint Capital's largest Q2 2026 buy was First Tracks Biotherapeutics: 622,723 shares worth $12.5M.
  • Stempoint Capital added most to Tango Therapeutics in Q2 2026, an estimated $25.3M increase.
  • Stempoint Capital's biggest Q2 2026 reduction was Scholar Rock, cutting an estimated $38.5M.
  • Stempoint Capital fully exited Syndax Pharmaceuticals in Q2 2026, selling an estimated $28.4M.
  • Stempoint Capital's ten largest holdings make up 41% of its $581M portfolio in Q2 2026.
  • Stempoint Capital opened 34 new positions and closed 32 in Q2 2026.
  • Stempoint Capital's portfolio value rose 11% quarter-over-quarter to $581M.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.